Smart jab can shrink head and neck cancer tumours within six weeks, trial finds

19 octobre 2025 | Andrew Gregory Health editor
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers Doctors have hailed “incredibly encouraging” trial results that show a triple-action smart jab can shrink tumours in head and neck cancer patients within six weeks. Head and neck (…)
 Site référencé:  The Guardian (Europe)

The Guardian (Europe) 

Landslide win for pro-EU Turkish Cypriot candidate raises hopes for peace
19/10/2025
Verstappen cruises to victory in F1 US Grand Prix to pile pressure on McLaren
19/10/2025
MPs urged to confront royal family over Prince Andrew’s Epstein links
19/10/2025
Slot concedes Liverpool face challenge after Manchester United’s Anfield win
19/10/2025
England invite Noah Caluori to training after sparkling five-try Prem debut
19/10/2025
Dead fish found on River Thet where large stretch of white foam appeared
19/10/2025